Amarillo Biosciences, Inc. (ABI) (OTC BB: AMAR) today announced that it had entered into a agency agreement with Dr. Claus Martin, President and CEO, Gesellschaft Fur Medizinisch and Technische Investionen mbH & CoKG (GMTI mbH & CoKG), a privately held German venture capital group, to commercialize low dose oral interferon (natural human IFN) in Thailand, Brunei, Myanmar, the Philippines, Malaysia, Singapore and Indonesia (the Territory).
